Evidence map›Paper›PMID 42565085›Full record

ArticleMaterials today. Bio2026

Self-assembled nano-PROTACs potentiate colorectal cancer immunotherapy via downregulating PD-L1 and GPX4 expression.

Xueping Luo, Yixin Liu, Guangmiao Chen, Xinrui Ma, Pingping Xu, Yutong Li, Longyu Zheng, Rongrong Zheng, Youqin Xu, Shiying Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xueping LuoKey Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510700, PR China.
Yixin LiuKey Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510700, PR China.
Guangmiao ChenGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, PR China.
Xinrui MaKey Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510700, PR China.
Pingping XuKey Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510700, PR China.
Yutong LiKey Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510700, PR China.
Longyu ZhengKey Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510700, PR China.
Rongrong ZhengGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, PR China.
Youqin XuKey Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510700, PR China.
Shiying LiGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, PR China.
Linping ZhaoKey Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The NMPA and State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510700, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis, a form of regulated cell death that is iron-dependent and driven by the accumulation of lipid peroxides (LPO), has emerged as a promising avenue for enhancing tumor immunogenicity and augmenting immune checkpoint blockade (ICB) efficacy. In this study, we demonstrated that dBET57, a BRD4-targeting PROTAC, potently suppresses the expression of GPX4, the master negative regulator of ferroptosis, thereby triggering ferroptotic cell death, while concurrently downregulating PD-L1 to reverse immune evasion. Based on this, we developed a self-assembled nano-PROTAC platform, termed dBET@TF, designed to amplify ferroptosis and potentiate colorectal cancer immunotherapy. Specifically, dBET@TF was constructed via self-assembly of dBET57, tannic acid, and Fe

Indexed as

FerroptosisImmunogenic cell deathImmunotherapyPROTACSelf-assembly

Identifiers

PMID42565085
PMCPMC13446093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.